Barcelona-based Biorce secures €3.5 million aiming to transform clinical trials through AI | EU-Startups

Biorce, a TechBio company focused on transforming clinical trials through artificial intelligence, has announced the completion of a €3.5 million funding round to accelerate the development of Biorce’s flagship AI model, Jarvis, which aims to streamline data accessibility in clinical trials.

The round led by YZR Capital and Mustard Seed Maze, with support from Outsized Ventures, Pathena Family Office, and Plug and Play Tech Center aims to further develop Biorce’s AI platform, including its flagship AI model, Jarvis, which aims to streamline clinical trial processes by offering real-time, cross-referenced data access for patients, physicians, and researchers.

Founded in 2024 by Pedro Coelho, Biorce seeks to address challenges in clinical trials, including inefficiencies, data fragmentation, and logistical complexities. “Clinical trials are crucial for drug development but remain hindered by inefficiencies, data fragmentation, and complex logistical challenges. We’re transforming this landscape through our multi-modality platform and Jarvis, our proprietary AI model, making trials faster, more efficient, and accessible to all,” said Pedro Coelho.

The Jarvis model provides a centralized source of real-time trial data, designed to improve access to information for stakeholders in the clinical trial process. By aggregating data from various sources, Jarvis aims to deliver timely insights and reduce the need for manual cross-referencing.

Markus Feuerecker, Founding Partner at YZR Capital, commented: “Biorce’s approach to integrating AI in clinical trials promises to bridge significant gaps in the industry. They built a cutting-edge product promising significant efficiency gains for their customers. We are excited to back the team behind Pedro, Clara, José, and Diogo, whose combined experience in CROs, clinical trials management, and programming gave them the required background to work on technologies that can redefine how we think about drug development.”

Sofia Queiroz, Principal at Mustard Seed Maze, stated: “Investing in Biorce aligns perfectly with our mission to back transformative solutions in healthcare. The clinical trial landscape is ripe for disruption, and Biorce’s end-to-end AI platform has the potential to dramatically reduce the time and cost it takes to bring life-saving drugs to patients by improving the protocol and feasibility phase of clinical trials. What particularly excites us is their unique approach to building network effects through private data partnerships across the entire clinical trial ecosystem.”

With this investment, Biorce aims to further its mission of enhancing clinical trial efficiency, supporting the process of bringing new treatments to market.